Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
gene editing
life sciences
national blog main
boston
boston blog main
boston top stories
crispr
editas medicine
enzyme
national top stories
san francisco blog main
san francisco top stories
agios therapeutics
allergan
base editing
branden moriarty
broad institute
cas13
clinical study
clinical trials
crispr therapeutics
crispr-cas9
cynthia collins
data
david liu
disease
dna
drugs
editor
editr
feng zhang
gag
genome editing
harvard university
hunter syndrome
ids
intellia therapeutics
john evans
katrine bosley
What
editing
4
×
gene
medicine
4
×
crispr
editas
humans
therapeutics
trial
allergan
beam
benefit
blessing
bosley
breathing
cas
ceo
check
clinical
close
colossal
companies
company
create
crispr’s
cusp
depart
editor
experimental
founders
going
gotten
growing
harvard
interested
investors
isn't
jump
katrine
landmark
little
Language
unset
Current search:
editing
×
biotech
×
medicine
×
@techcrunch.com
2 years ago
How Colossal sold investors on a quest to resurrect a woolly mammoth
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M